Diagnosing diabetic neuropathy

Something old, something new

Ioannis N. Petropoulos, Georgios Ponirakis, Adnan Khan, Hamad Almuhannadi, Hoda Gad, Rayaz Malik

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

There are potentially many ways of assessing diabetic peripheral neuropathy (DPN). However, they do not fulfill U.S. Food and Drug Administration (FDA) requirements in relation to their capacity to assess therapeutic benefit in clinical trials of DPN. Over the past several decades symptoms and signs, quantitative sensory and electrodiagnostic testing have been strongly endorsed, but have consistently failed as surrogate end points in clinical trials. Therefore, there is an unmet need for reliable biomarkers to capture the onset and progression and to facilitate drug discovery in DPN. Corneal confocal microscopy (CCM) is a non-invasive ophthalmic imaging modality for in vivo evaluation of sensory C-fibers. An increasing body of evidence from multiple centers worldwide suggests that CCM fulfills the FDA criteria as a surrogate endpoint of DPN.

Original languageEnglish
Pages (from-to)255-269
Number of pages15
JournalDiabetes and Metabolism Journal
Volume42
Issue number4
DOIs
Publication statusPublished - 1 Aug 2018

Fingerprint

Diabetic Neuropathies
Peripheral Nervous System Diseases
Biomarkers
United States Food and Drug Administration
Confocal Microscopy
Clinical Trials
Unmyelinated Nerve Fibers
Drug Discovery
Signs and Symptoms
Therapeutics

Keywords

  • Complications
  • Diabetic neuropathies
  • Diagnosis

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Diagnosing diabetic neuropathy : Something old, something new. / Petropoulos, Ioannis N.; Ponirakis, Georgios; Khan, Adnan; Almuhannadi, Hamad; Gad, Hoda; Malik, Rayaz.

In: Diabetes and Metabolism Journal, Vol. 42, No. 4, 01.08.2018, p. 255-269.

Research output: Contribution to journalReview article

@article{9e5c9358cb104b05a77c7a3bc2c23c59,
title = "Diagnosing diabetic neuropathy: Something old, something new",
abstract = "There are potentially many ways of assessing diabetic peripheral neuropathy (DPN). However, they do not fulfill U.S. Food and Drug Administration (FDA) requirements in relation to their capacity to assess therapeutic benefit in clinical trials of DPN. Over the past several decades symptoms and signs, quantitative sensory and electrodiagnostic testing have been strongly endorsed, but have consistently failed as surrogate end points in clinical trials. Therefore, there is an unmet need for reliable biomarkers to capture the onset and progression and to facilitate drug discovery in DPN. Corneal confocal microscopy (CCM) is a non-invasive ophthalmic imaging modality for in vivo evaluation of sensory C-fibers. An increasing body of evidence from multiple centers worldwide suggests that CCM fulfills the FDA criteria as a surrogate endpoint of DPN.",
keywords = "Complications, Diabetic neuropathies, Diagnosis",
author = "Petropoulos, {Ioannis N.} and Georgios Ponirakis and Adnan Khan and Hamad Almuhannadi and Hoda Gad and Rayaz Malik",
year = "2018",
month = "8",
day = "1",
doi = "10.4093/dmj.2018.0056",
language = "English",
volume = "42",
pages = "255--269",
journal = "Diabetes and Metabolism Journal",
issn = "2233-6079",
publisher = "Korean Diabetes Association",
number = "4",

}

TY - JOUR

T1 - Diagnosing diabetic neuropathy

T2 - Something old, something new

AU - Petropoulos, Ioannis N.

AU - Ponirakis, Georgios

AU - Khan, Adnan

AU - Almuhannadi, Hamad

AU - Gad, Hoda

AU - Malik, Rayaz

PY - 2018/8/1

Y1 - 2018/8/1

N2 - There are potentially many ways of assessing diabetic peripheral neuropathy (DPN). However, they do not fulfill U.S. Food and Drug Administration (FDA) requirements in relation to their capacity to assess therapeutic benefit in clinical trials of DPN. Over the past several decades symptoms and signs, quantitative sensory and electrodiagnostic testing have been strongly endorsed, but have consistently failed as surrogate end points in clinical trials. Therefore, there is an unmet need for reliable biomarkers to capture the onset and progression and to facilitate drug discovery in DPN. Corneal confocal microscopy (CCM) is a non-invasive ophthalmic imaging modality for in vivo evaluation of sensory C-fibers. An increasing body of evidence from multiple centers worldwide suggests that CCM fulfills the FDA criteria as a surrogate endpoint of DPN.

AB - There are potentially many ways of assessing diabetic peripheral neuropathy (DPN). However, they do not fulfill U.S. Food and Drug Administration (FDA) requirements in relation to their capacity to assess therapeutic benefit in clinical trials of DPN. Over the past several decades symptoms and signs, quantitative sensory and electrodiagnostic testing have been strongly endorsed, but have consistently failed as surrogate end points in clinical trials. Therefore, there is an unmet need for reliable biomarkers to capture the onset and progression and to facilitate drug discovery in DPN. Corneal confocal microscopy (CCM) is a non-invasive ophthalmic imaging modality for in vivo evaluation of sensory C-fibers. An increasing body of evidence from multiple centers worldwide suggests that CCM fulfills the FDA criteria as a surrogate endpoint of DPN.

KW - Complications

KW - Diabetic neuropathies

KW - Diagnosis

UR - http://www.scopus.com/inward/record.url?scp=85052112722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052112722&partnerID=8YFLogxK

U2 - 10.4093/dmj.2018.0056

DO - 10.4093/dmj.2018.0056

M3 - Review article

VL - 42

SP - 255

EP - 269

JO - Diabetes and Metabolism Journal

JF - Diabetes and Metabolism Journal

SN - 2233-6079

IS - 4

ER -